AugurSignals.com

Follow us for great insights in public companies. Visit AugurSignals com for Insider News, Personalized Stock Pickers, and Watchlist / Portfolio Alert Trackers.

[AugurSignals.com @AugurSignals]

🚨 Insider Insight: John Hasan Ruiz, CEO of #MSPRecovery ($LIFW), recently acquired nearly 374K shares amidst a volatile healthcare market. Stock price dropped from a high of $17.48 to $0.26 - is now the time to go in? #HealthcareTech #InsiderTrading

[AugurSignals.com @AugurSignals]

🚨 Insider Insight: Nancy Lurker, CEO of #EyePointPharma ($EYPT), recently acquired shares amidst a volatile biotech market. Is this a sign of upcoming breakthroughs in retinal disease treatments? #BiotechWatch #HealthcareInvesting #WetAMD #NPDR #DME

[AugurSignals.com @AugurSignals]

Has the CEO not enough lost on this one? #insidertrading #loosing

[AugurSignals.com @AugurSignals]

🔍 Insider Alert: Vahanna Tech Edge Acquisition I Corp. (RDZN) update! 🧐

[AugurSignals.com @AugurSignals]

🚀 Frederic Salerno just bought 5k shares of Madison Square Garden Entertainment Corp. (MSGE)! After $MSGE’s stellar FY2024 results, with revenues soaring 13% to $959.3M 📈. Operating income also exceeded expectations, signaling big things ahead! 💼🔥 #Investing #MSGE #InsiderTrading

[AugurSignals.com @AugurSignals]

Joseph P. Slattery’s recent purchase of 2,985 shares of CVRx, Inc. likely reflects his confidence in the company’s future prospects, especially in light of recent developments. CVRx has been making strategic moves, including increasing reimbursement rates for its key Barostim therapy starting in 2025, which could significantly boost revenue. The company also reported a 24% revenue increase in the second quarter of 2024, although it still posted a net loss.

[AugurSignals.com @AugurSignals]

David J. Lee’s recent acquisition of 8,155 shares in WEBTOON Entertainment Inc. (WBTN) seems to be a strategic move amidst a challenging period for the company. Following its IPO, WEBTOON’s second-quarter earnings fell short of expectations, leading to a significant drop in its stock price—down by over 38% in a single day. The disappointing financial performance was attributed to costs related to the IPO, stock-based compensation, and unfavorable currency exchange rates.

[AugurSignals.com @AugurSignals]

Kymera Therapeutics, Inc., a company in the Healthcare sector, has reported insider trading activity. Baker Bros. Advisors Lp, a Director, a 10%+ Owner, acquired 347572.0 Prefunded Warrants based on 347572.0 of Common Stock. The market value of the shares involved in the transaction is $ 16,874,620.

[AugurSignals.com @AugurSignals]

Pulmonx CEO Steven S. Williamson acquires 14,245 shares of $LUNG, With an aging population and a shift towards minimally invasive treatments, Pulmonx’s innovative solutions for severe lung disease advanced COPD care! #InsiderTrading

[AugurSignals.com @AugurSignals]

Frederic Salerno’s recent purchase of 5,000 shares of Madison Square Garden Entertainment Corp. ($MSGE) appears to be a vote of confidence in the company’s strong performance and positive outlook. MSGE recently reported robust financial results for the fiscal year 2024, with revenues growing by 13% year-over-year to $959.3 million, surpassing the high end of their guidance. The company also saw significant growth in operating income and adjusted operating income, both of which exceeded expectations.

[AugurSignals.com @AugurSignals]

Frederic Salerno’s recent purchase of 5,000 shares of Madison Square Garden Entertainment Corp. ($MSGE) appears to be a vote of confidence in the company’s strong performance and positive outlook. MSGE recently reported robust financial results for the fiscal year 2024, with revenues growing by 13% year-over-year to $959.3 million, surpassing the high end of their guidance. The company also saw significant growth in operating income and adjusted operating income, both of which exceeded expectations.

[AugurSignals.com @AugurSignals]

Pulmonx CEO Steven S. Williamson acquires 14,245 shares of $LUNG, With an aging population and a shift towards minimally invasive treatments, Pulmonx’s innovative solutions for severe lung disease advanced COPD care! #InsiderTrading

[AugurSignals.com @AugurSignals]

Kymera Therapeutics, Inc., a company in the Healthcare sector, has reported insider trading activity. Baker Bros. Advisors Lp, a Director, a 10%+ Owner, acquired 347572.0 Prefunded Warrants based on 347572.0 of Common Stock. The market value of the shares involved in the transaction is $ 16,874,620.

[AugurSignals.com @AugurSignals]

Would you invest in MSP Recovery $LIFW at $0.4
- considering the CEO's significant insider buying?

[AugurSignals.com @AugurSignals]

https://t.co/PKOrZJjPPX

[AugurSignals.com @AugurSignals]

This represents a massive patient need $EYPT is targeting.
What is the most likely outcome?

[AugurSignals.com @AugurSignals]

Nancy Lurker, CEO of EyePoint Pharmaceuticals, acquires 3,173 shares, showing confidence in $EYPT’s future. As the company gears up for Phase 3 trials of DURAVYU™, its innovative treatment for retinal diseases, could this be a pivotal moment in advancing eye care? With an aging population and growing demand for sustained treatments, all eyes are on EyePoint. #Biotech #InsiderTrading #RetinalTherapy

[AugurSignals.com @AugurSignals]

Wet Age-Related Macular Degeneration (Wet AMD):
The prevalence of AMD, which includes wet AMD, varies significantly by region but can be as high as 18.3% in some states for the general population, according to the CDC's Vision and Eye Health Surveillance System (VEHSS). However, these figures include all stages of AMD. Specifically for wet AMD, while exact numbers for the U.S. in 2024 aren't provided, it's known that wet AMD accounts for about 10-15% of all AMD cases but is responsible for 90% of severe vision loss from AMD. Given the aging population, if we extrapolate from past data, millions suffer from wet AMD, but an exact current number isn't directly cited.
Non-Proliferative Diabetic Retinopathy (NPDR):
NPDR is a common condition among diabetic patients. While exact numbers for NPDR alone in 2024 aren't provided, diabetic retinopathy (which includes NPDR) affects approximately 28.5% of diabetic patients over 12 years old in the U.S. Given that NPDR is the earlier stage of diabetic retinopathy, it's safe to say a significant portion of these cases would be NPDR, but exact figures for NPDR specifically aren't detailed.
Diabetic Macular Edema (DME):
The prevalence of DME varies widely but has been reported to range from 1.4% to 5.57% in people with type 2 diabetes mellitus (T2DM) and 4.2% to 14.3% in those with type 1 diabetes mellitus (T1DM). Given the high prevalence of diabetes, even these percentages translate to a significant number of individuals. However, without specific 2024 data, we rely on these ranges for estimation.

[AugurSignals.com @AugurSignals]

Abdiel Capital Advisors increases its stake in Appian Corp with a $1.57M purchase of 24,257 shares.Despite market volatility, Appian’s low-code automation platform positions it well in a competitive landscape, potentially offering substantial upside.#TechInvesting #InsiderTrading